KR810002012B1 - Process for preparing preparations for oral administration - Google Patents

Process for preparing preparations for oral administration Download PDF

Info

Publication number
KR810002012B1
KR810002012B1 KR7600234A KR760000234A KR810002012B1 KR 810002012 B1 KR810002012 B1 KR 810002012B1 KR 7600234 A KR7600234 A KR 7600234A KR 760000234 A KR760000234 A KR 760000234A KR 810002012 B1 KR810002012 B1 KR 810002012B1
Authority
KR
South Korea
Prior art keywords
midecamycin
added
solvent
dissolving
granules
Prior art date
Application number
KR7600234A
Other languages
Korean (ko)
Inventor
도시유기 고바야시
아끼오 오까다
다께시 마야마
아끼라 오까다
Original Assignee
나까가와 다게시
메이지 셰이가 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나까가와 다게시, 메이지 셰이가 주식회사 filed Critical 나까가와 다게시
Priority to KR7600234A priority Critical patent/KR810002012B1/en
Application granted granted Critical
Publication of KR810002012B1 publication Critical patent/KR810002012B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Palatable compns. contg. bitter active ingredients are prepd. by di-solving a substance which conceals the bitterness in a solvent contg. the active ingredient, and adding anhyd. silicic acid to form a powder. Thus, granules were prepd. from a 2L CH2Cl2 soln. contg. midecamycin 1kg to which ethyl cellulose 1 kg, was added. Sufficient arom. granules, comprising mannitol-Na saccharin (10:30 by wt.), were then mixed in to produce a prepn. contg. 100mg midecamycin/g.

Description

경구용 제제(經口用製劑)의 제법Preparation of oral preparations

본 발명은 복용할 때 쓴맛을 나타내는 의약품의 고미(苦味)를 특수한 제제화(製劑化) 방법으로 마스크(Mask)하는 것을 특징으로 하는 경구용제제의 제법에 관한 것이다.The present invention relates to a method for the preparation of an oral solvent, characterized in that the mask of bitter taste of a medicine having a bitter taste when taken by a special formulation method.

일반적으로 의약품을 내복(內服)으로 할때 불쾌한 맛, 특히 쓴만 또는 좋지 않은 자극성을 갖고있는 것이 많으며, 이들 가운데 극히 중요한 의약품, 예컨데 미데카마이신, 키다사마이신, 조사마이신, 에리스트마이신 등 마크로타이드계 항생물질, 테트라사이클린계 항생물질, 클로람페니콜 등의 항생물질이나 염산 클로르프로마진, 염산 에타페논, 염산 포르민(buformin) 등의 합성의약품 등 기타 다수가 있다.In general, when the medicine is an oral (內服), many of them have an unpleasant taste, especially bitterness or bad irritation, among them extremely important medicines, for example, macrodemic, such as midecamycin, kidasamycin, probemycin, erythromycin Antibiotics, tetracycline antibiotics, antibiotics such as chloramphenicol, and synthetic drugs such as chlorpromazine hydrochloride, etaphenone hydrochloride, and buformin hydrochloride.

그런데, 여기서 본 발명자들은 이들 의약품을 내복하기 용이하게 하는 제제화법의 연구를 주도면밀하게 계속한 결과 미데카마이신, 키다사마이신, 조사마이신 등 마크로라이드계 항생물질의 고미의 마스크법으로서 본 발명을 완성한 것이다.By the way, the present inventors have conducted the study of the formulation method which makes these medicines easy to undertake, and as a result, the present invention is used as a masking method of bitumen of macrolide antibiotics such as midecamycin, kidasamycin, and probemycin. It is completed.

본 발명의 의약품을 용해시키든가 또는 현탁시킬 수 있는 용제에 고미의 마스크물질을 고농도로 용해하고 또 여기에 의약품을 용해 또는 현탁시키거나, 의약품을 고미의 마스크물질을 용해한 용제에 용해 또는 현탁하여, 여기에 고미의 마스크물질을 가하여 혼합 교반하고, 경질 무수규산을 가하여 분말화한 다음 고미의 마스크물질의 용액을 사용하여 조립(組立) 제제화하는 방법이다.Dissolving or suspending the masking material of high taste in a solvent capable of dissolving or suspending the medicine of the present invention at high concentration and dissolving or suspending the medicine therein, or dissolving or suspending the medicine in a solvent which dissolves the masking material of high taste, It is a method of adding a masking substance of bitter rice to it, mixing and stirring, adding hard silicic anhydride to make powder, and then granulating and formulating it using a solution of bitter mask material.

즉, 본 방법은 의약품을 용해 또는 현탁시키면서 고미의 마스크물질을 용해한 용제에 용해 또는 현탁시킨다는 점에 그 특징을 갖고 있다.That is, this method has the characteristics that it dissolves or suspends in the solvent which melt | dissolved the masking material of bitter rice, while dissolving or suspending a medicine.

본 발명에 의하면 상기의 약품에서 경구용제제를 제조할 경우 의약품을 용해 또는 현탁시키는 용제에 고미의 마스크물질을 고농도로 용해시킨 다음 여기에 의약품을 가하여 잘 니딩(kneading)한다.According to the present invention, when preparing an oral solvent in the above medicine, the masking material of high taste is dissolved in a high concentration in the solvent for dissolving or suspending the medicine, and then the medicine is added and kneaded well.

또는 고미의 마스크물질을 용해시키는 용제에 의약품을 용해 또는 현탁시킨 다음 고미의 마스크 물질을 혼합, 니당한다.Alternatively, the drug is dissolved or suspended in a solvent that dissolves the masking material of bitter rice, and the mask material of bitter meat is mixed and treated.

이와같이 한 다음 경질무수규산을 가하여 분말화하고 다음에 조쇄(粗碎), 건조, 분쇄를 한다.This is followed by the addition of hard silicic anhydride to pulverization, followed by crushing, drying and grinding.

이와 같은 조작으로 상기 의약품의 고미의 약 50%를 마스크하고 다음에 고미의 마스크물질을 사용하여 유동층조립기에 의해 그 분말을 조립하여 남아있는 고미를 마스크 함으로써 고미가 없는 입제로 된다.This operation masks about 50% of the bitters of the medicine, and then the mask material of the bitters is used to assemble the powder by means of a fluid bed granulator to mask the remaining bitters to obtain a bitter-free granule.

즉, 고미의 마스크물질을 용해한 상태로 상기 의약품을 혼합, 니딩하는 조작과 고미의 마스크물질을 사용하여 유동층조립기 중에서 조립하는 조작을 병행함으로써 고미를 완전히 마스크하는 것을 특징으로하는 고미가 없는 경구용제제의 제법이다.In other words, the blemish-free oral solvent characterized in that masking blemishes completely by performing the operation of mixing and kneading the medicines in the state of dissolving the masking material of the bitter rice and assembling in a fluidized bed granulator using the masking material of bitter meat It is the recipe of.

제제에 맛을 부가하는데도 별도로 설탕, 만나톨(mannitol), 삭카린, 구연산, 식염 등 적당한 교미제를 가하여 통상의 방법과 같이 조립하는 것과 상기의 입제와 혼합하면 다시 맛좋게 복용이 용이하고 어린이에게도 복용이 가능한 입제를 얻을 수 있다.In addition to adding flavor to the preparations, sugar, mannitol, saccharin, citric acid, salts, etc. are added to the appropriate mating agent and assembled in the usual way. You can get granules that you can take.

고미의 마스크물질로서는 물에 불용성인 의약품 고분자물질, 예컨데 에틸셀룰로오스, 하이드록시프로필메틸 셀룰로오스프탈레이트, 셀룰로오스 아세테이트 프탈레이트, 폴리비닐 아세탈디에틸 아미노 아세테이트, 디메틸 아미노 에틸메타아크릴산, 메틸메타아크릴산 공중합체, 메틸비닐피리딘 메틸아크릴레이트메타아크릴산 공중합체 등의 1종 또는 2종 이상을 사용할 수 있다.As a masking material of bitter rice, a pharmaceutical high molecular material insoluble in water, such as ethyl cellulose, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, polyvinyl acetaldiethyl amino acetate, dimethyl amino ethyl methacrylic acid, methyl methacrylic acid copolymer, methyl vinyl 1 type, or 2 or more types, such as a pyridine methylacrylate methacrylic acid copolymer, can be used.

이에 또 상기의 고미마스크물질은 의약품의 0.5-3배량으로 충분하며, 또 조립에 있어서는 그

Figure kpo00001
량 정도를 사용하면 된다. 경질 무수규산량은 특히 규정되어 있는 것은 아니나 고미마스크 물질과 동일량 이하로 충분히 분말화된다. 다음 실시예에서 다시 상세히 설명한다.In addition, the above-mentioned high-masking substance is sufficient in the amount of 0.5-3 times of the medicine, and in the assembly
Figure kpo00001
You can use the quantity. The amount of hard silicic anhydride is not particularly specified but is sufficiently powdered to the same amount or less as the high-mask material. This will be described in detail again in the following examples.

[실시예 1]Example 1

염화메틸렌 2ℓ중에 미데카마이신 1kg(역가)을 용해하여 얻은 용액에 에틸셀룰로오스 1kg을 첨가하여 충분히 다우믹사를 써서 니딩한 다음 경질무수규산 0.9kg을 첨가하여 니딩하고 분말화하여 50℃에서 3시간 건조한 다음 분쇄한다.1 kg of ethyl cellulose was added to a solution obtained by dissolving 1 kg of midecamycin (titer) in methylene chloride, and then kneaded using Daumic Inc., then kneaded by adding 0.9 kg of hard silicic anhydride, and dried at 50 ° C. for 3 hours. Then crush.

유동층 조립기를 사용하여 에틸셀룰로우스의 2% 1,1,1-트리클로에탄 용액에 에틸셀룰로오스로서 160g을 써서 상기분체의 조립을 하여 고미를 마스크한 의약품 조립체를 얻었다.Using a fluidized bed granulator, 160 g of ethyl cellulose was used as a 2% 1,1,1-trichloroethane solution of ethyl cellulose to granulate the powder to obtain a medicine assembly masking bitter rice.

한편, 별도로 만니톨 10kg, 삭카린나트륨 30g을 혼합하여 얻은 혼합물을 하이드록시 프로필셀룰로오스 수용액을 써서 통상의 방법으로 조립하여 교미용입상체로 한다.On the other hand, a mixture obtained by separately mixing 10 kg of mannitol and 30 g of sodium saccharin is granulated by a conventional method using an aqueous solution of hydroxy propyl cellulose to obtain a granule granule.

상기 의약품 입상체와 상기 교미용 입상체 및 향로미량을 사용하여 1g당 미데카마이신 함량 100mg(역가)이 되게 혼합하여 고미가 없이 복용하기 쉬운 미데카마이신의 세립재를 얻었다.The drug granules, the granules for copulation, and the amount of fragrances were mixed so that the content of midecamycin was 100 mg (titer) per 1 g, thereby obtaining fine grains of midecamycin that could be easily taken without gummy.

좀더 구체적으로 설명하면 본법에 의한 미데카마이신 세립(본 시료를 A로 함)과 일반적인 조립법으로 하여 미데카마이신 1kg(역가), 삭카린나트륨 30g, 향료미량, 여기에 만니톨을 가하여 10kg으로 한 다음, 유동층 조립기에 의하여 하이드록시 프로필셀룰로오스의 2% 수용액에 의해 조립한 1g당 미데카마이신 100mg(역가)의 세립재(본 시료를 B로 함)의 두시료에 대해 패널(panel) 20인(人)에게 순서효과를 고려하여 상기 2종의 시료를 나누어, 고미의 비교 관능시험을 일반적으로 약을 복용하는 방법으로 하여 2점 기호시험법에 의해 실시하였다.In more detail, by using the fine granules of midecamycin according to this method (this sample is called A) and general granulation method, 1 kg of midecamycin (titer), 30 g of saccharin sodium, a small amount of flavor, and 10 mg of mannitol were added thereto. 20 panels for two samples of fine granules of 100 mg (titer) of midecamycin (titer) (g) prepared by 2% aqueous solution of hydroxypropyl cellulose by means of a fluidized bed granulator. In consideration of the order effect, the two samples were divided, and a comparative sensory test of bitter rice was carried out by a two-point taste test method as a method of generally taking medicine.

그 결과 본법에 의한 미데카마이신세립은 쓰지 않고 대단히 복용하기 쉬운 약제임이 다시 판명되었다.As a result, it was again found that midecamycin granules under this law were very easy to take without being used.

Figure kpo00002
Figure kpo00002

[실시예 2]Example 2

염화메틸렌 2ℓ중에 에틸셀룰로오스 1kg을 용해하여 얻은 용액에 미데카마이신 1kg(역가)에 첨가하여 충분히 니딩한 다음 경질무수규산 0.9kg을 첨가하여 니딩해서 분말화하여 50℃에서 3시간 건조한 다음 실시예 1에 기재한 조작과 동일하게 처리하여 고미가 없는 복용하기 용이한 디데카마이신의 세립제를 얻었다.1 kg of midecamycin was added to the solution obtained by dissolving 1 kg of ethyl cellulose in 2 l of methylene chloride, and then kneaded sufficiently, followed by kneading by adding 0.9 kg of hard silicic anhydride and drying at 50 ° C. for 3 hours. It processed similarly to the procedure described in the above, and obtained an easy-to-take fine decamycin granule agent.

[실시예 3]Example 3

디메틸아미노 에틸메타아크릴산-메틸 메타아크릴산 공중합체 1kg을 염화메틸렌 1.5ℓ에 용해하여 얻은 용액을 미데카마이신 1kg(역가)에 첨가하여 충분히 니딩한 다음 경질무수규산 1kg을 첨가하여 니딩하고 분말화하여 40℃에서 3시간 건조한 다음 분쇄한다. 이 분체를 유동층 조립기를 써서 에틸 셀룰로오스의 2% 1,1,1-트리클로로에탄 용액에 에틸셀룰로오스로서 200g을 사용하여 조립하였다.A solution obtained by dissolving 1 kg of dimethylamino ethylmethacrylic acid-methyl methacrylic acid copolymer in 1.5 l of methylene chloride was added to 1 kg of midecamycin (titer) and kneaded sufficiently, then 1 kg of hard silicic anhydride was added, kneaded, and powdered. It is dried for 3 hours at ℃ and then pulverized. This powder was granulated using a fluidized bed granulator using 200 g of ethyl cellulose in a 2% 1,1,1-trichloroethane solution of ethyl cellulose.

이하 실시예 1과 동일하게 실시하여 고미가 없이 복용하기 용이한 미데카마이신의 세립제를 얻었다.It was carried out in the same manner as in Example 1 below to obtain a fine agent of midecamycin that can be easily taken without bitterness.

[실시예 4]Example 4

조사마이신 1kg(역가)을 사용하여 이하 실시예 1과 동일하게 조작해서 1g당 조사마이신 함량 100mg(역가)의 고미없이 복용하기 용이한 조사마이신의 세립제를 얻었다.1 kg of irradiated mycin (titer) was used in the same manner as in Example 1 below to obtain a fine granule of irradiated mycomycin that was easy to take without a tare of 100 mg of irradiated mycosin per titer (g).

[실시예 5]Example 5

키타사마이신 1kg(역가)를 사용하여 이하 실시예 1과 동일하게 조작하여 1g당 키타사마이신 함량 100mg(역가)의 고미없이 복용하기 용이한 키타마이신의 세립을 얻었다.Using 1 kg of kitasamycin (titer) in the same manner as in Example 1 below, fine granules of easy-to-take kitamimycin without gummy having a content of 100 mg (titer) of kitasamycin per gram were obtained.

[실시예 6]Example 6

에틸셀룰로오스 3kg을 1,1,1-트리클로로에탄 28ℓ중에 용해하고 여기에 염산 부포르민 1kg을 첨가하여 니더(kneader)에 의해 충분히 니딩하고 염산 부포르민을 에틸셀룰로오스 중에서 충분히 분산시킨다.3 kg of ethyl cellulose is dissolved in 28 L of 1,1,1-trichloroethane, and 1 kg of buformin hydrochloride is added thereto, kneading is sufficiently carried out by kneader, and the buformin hydrochloride is sufficiently dispersed in ethyl cellulose.

얻어진 분산체중에서, 다음의 합성 규산알미늄을 서서히 첨가하면서 니딩 교반하여 분말화하고, 감압하에서 50℃ 3시간 건조한 다음 분쇄한다.In the obtained dispersion, the following synthetic aluminum silicate is slowly kneaded while powdered by kneading with stirring, and then dried under reduced pressure at 50 ° C. for 3 hours and then pulverized.

에틸셀룰로오스의 2% 1,1,1-트리클로로에탄 용액 및 유동층 조립기를 사용하여 상기 분상체의 조립을 한다.The powdery bodies are assembled using a 2% 1,1,1-trichloroethane solution of ethyl cellulose and a fluidized bed granulator.

한편, 상기 조립과는 별개로 만니톨 6kg, 삭카린 60g 및 식염 60g을 혼합하여 얻은 혼합물을 하이드록시프로필 셀룰로오스의 2% 수용액을 써서 조립한다.On the other hand, apart from the granulation, a mixture obtained by mixing 6 kg of mannitol, 60 g of saccharin and 60 g of salt is assembled using a 2% aqueous solution of hydroxypropyl cellulose.

상기 의약품조성물 입상체와 상기 교미용 입상체를 혼합하면 맛이 좋으며 고미가 없는 복용하기 용이한 염산 부포르민 과립제가 얻어진다.Mixing the pharmaceutical composition granules with the granulation granules gives an easy-to-take hydrochloric acid buformin granule without taste.

[실시예 7]Example 7

염화메틸렌 10ℓ중에 소르비탄세스키오리에이트(sorbitan sequioleate) 50g을 용해하여 얻은 용액 중에 클로람페니콜 1kg(역자)을 현탁 분산시킨 다음 에틸셀룰로오스 2.22kg을 첨가하여 충분히 니딩한다.1 kg of chloramphenicol is suspended and dispersed in a solution obtained by dissolving 50 g of sorbitan sequioleate in 10 l of methylene chloride, followed by sufficient kneading by adding 2.22 kg of ethyl cellulose.

이와같이 처리한 다음 경질무수규산 2kg을 첨가하여 니딩하고 분말화하여 60℃에서 3시간 건조한 다음 분쇄한다.After treating in this way, 2 kg of hard silicic anhydride is added, kneaded, powdered, dried at 60 ° C. for 3 hours, and then ground.

에틸셀룰로오스의 2% 1,1,1-트리클로로에탄 용액 및 유동층 조립기를 사용해서 상기 분상체의 조립을 한다. 한편, 상기 조립과는 별개로 만니톨 10kg, 삭카린 100g 및 식염 100g을 혼합하여 얻은 혼합물을 하이드록시 프로필셀룰로오스의 6% 이소프로필알콜 용액을 써서 통상의 방법으로 조립한다.The powdery bodies are granulated using a 2% 1,1,1-trichloroethane solution of ethyl cellulose and a fluidized bed granulator. On the other hand, apart from the granulation, a mixture obtained by mixing 10 kg of mannitol, 100 g of saccharin and 100 g of salt is assembled by a conventional method using a 6% isopropyl alcohol solution of hydroxypropyl cellulose.

위의 약품 조성물 입상체와 위 교미용입상체를 6 : 4의 비율로 혼합하면 맛이 좋고 안정한 클로람페니콜 과립제가 얻어진다.A tasty and stable chloramphenicol granule is obtained by mixing the above pharmaceutical composition granules with the above agitation granules in a ratio of 6: 4.

[실시예 8]Example 8

물 5ℓ중에 3kg의 하이드록시프로필메틸셀룰로오스 프탈레이트와 2g의 폴리솔베이트 80(polyoxyethylene sorbitan monooleate)을 현탁 내지 용해시킨 다음, 0.1N 수산화나트륨 용액을 가하여 pH를 7.0으로 유지하면서 교반 용해시킨다.In 5 liters of water, 3 kg of hydroxypropylmethylcellulose phthalate and 2 g of polysorbate 80 (polyoxyethylene sorbitan monooleate) are suspended or dissolved, and then 0.1 N sodium hydroxide solution is added to dissolve and stirred while maintaining the pH at 7.0.

얻어진 용액에 미데카마이신 1kg(역가)를 첨가하고 교반니딩하여 미데카마이신을 충분히 분산시킨 다음 경질무수규산 4kg을 가하고 다시 충분히 니딩하여 60℃에서 3시간 건조한 다음 실시예 6에 기재한 조작과 동일하게 처리하며 고미없는 안정한 미데카마이신 과립제가 얻어진다.To the obtained solution, 1 kg (titer) of midecamycin was added, stirred and kneaded to sufficiently dissolve midecamycin, 4 kg of hard silicic anhydride was added thereto, and further kneaded, dried at 60 ° C. for 3 hours, and then the same as the operation described in Example 6. And a stable midemycin granule is obtained.

Claims (1)

고미를 나타내는 마크로라이드계 항생물질의 경구용제제를 제조하는 방법에 있어서, 위 항생물질을 용해 또는 현탁시킨 용제에 고미마스크 물질을 고농도로 용해시키고, 또 여기에 위 항생물질을 가하여 교반 니딩하든가, 고미마스크 물질을 용해시키는 용제에 상기 항생물질을 용해 또는 현탁시킨 액과 고미마스크 물질을 교반니딩한 다음, 경질무수규산을 가해 분말로 하여 상기 고미마스크물질의 용액을 사용하여 조립하는 것을 특징으로 하는 고미를 갖고 있지 아니한 경구용제제의 제법.In the method for preparing an oral solvent of macrolide antibiotics exhibiting high taste, the high-masking substance is dissolved in a high concentration in a solvent in which the above antibiotic is dissolved or suspended, and the above antibiotic is added thereto, followed by stirring kneading. After stirring and kneading the solution obtained by dissolving or suspending the antibiotic material and the gomi mask material in a solvent for dissolving the gomi mask material, it is added to a powder of hard anhydrous silicic acid to assemble using a solution of the gomi mask material. Preparation of oral solvents that do not have bitter taste.
KR7600234A 1976-01-29 1976-01-29 Process for preparing preparations for oral administration KR810002012B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR7600234A KR810002012B1 (en) 1976-01-29 1976-01-29 Process for preparing preparations for oral administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR7600234A KR810002012B1 (en) 1976-01-29 1976-01-29 Process for preparing preparations for oral administration

Publications (1)

Publication Number Publication Date
KR810002012B1 true KR810002012B1 (en) 1981-12-15

Family

ID=19201932

Family Applications (1)

Application Number Title Priority Date Filing Date
KR7600234A KR810002012B1 (en) 1976-01-29 1976-01-29 Process for preparing preparations for oral administration

Country Status (1)

Country Link
KR (1) KR810002012B1 (en)

Similar Documents

Publication Publication Date Title
CA1069047A (en) Process for preparing preparations for oral administration
KR100404293B1 (en) Composition for Oral Administration
JP2685403B2 (en) Bitter drug taste-masking composition
JP3265680B2 (en) Oral pharmaceutical composition
RU2241460C2 (en) Cefuroxime axetyl-containing pharmaceutical composition with masked bitter taste
KR19990001564A (en) Azole antifungal agents with improved solubility and preparations containing them
KR19990067265A (en) Aqueous Granulation Method of Clarithromycin
KR20040058360A (en) A synthetic sweetener
JPS63112514A (en) Spray dried acetaminophen
JP2003073261A (en) Method for producing pharmaceutical solid preparation including sparingly soluble medicament
US3872227A (en) Formulation for oral administration of penicillins having improved taste properties
KR19980070732A (en) Method for preparing flavor masking agent of antibacterial active quinolone derivative
JPH0717866A (en) Medicinal composition
BRPI0619934A2 (en) extended release pharmaceutical composition, process for preparing a composition, use of a composition, and, use of a composition
JP2004529178A (en) Taste masking pharmaceutical composition
JPH06100602A (en) Solid oral preparation and production thereof
KR810002012B1 (en) Process for preparing preparations for oral administration
TWI286072B (en) Sleeping medicine formed by coating solid
JPH0383922A (en) Ibuprofen-containing composition for oral administration
JPH05255075A (en) Production of taste-modifying peroral composition
EP0563697B1 (en) Cytarabine ocfosfate hard capsule
JP4384278B2 (en) Ibuprofen-containing granules
JPS58401B2 (en) The antlers of the world
JPS63267720A (en) Sustained release preparation of emorfazone
JPH02206A (en) Novel drug preparation containing exifone and water-soluble polymeric compound